At the crossroads of health, wellness, technology, and marketing

2015 Marketing Summit Template_BLOGIt was a privilege to attend the 2015 Marketing Summit hosted by Ogilvy CommonHealth and eConsultancy. As the producer at the event, I was able to spend some time with each of the presenters. I was also able to hit the 10,000-step mark on my Fitbit by 3 pm—I’ll circle back to wearables later. I was most impressed by the diversity of speakers who are playing at the crossroads of health, wellness, technology, and marketing. The people I met and the messages I heard made me extremely excited on two different fronts: as a human being, and as a marketer.

As a human being, I was excited about the ideas surrounding personalized health that we heard throughout the day—especially since I moonlight as a fitness instructor.

Among them was Jeff Arnold from Sharecare, who is empowering consumers to take charge of their health by delivering personalized resources and expert advice through their online health profiles. Melissa Bojorquez of Physicians Interactive talked to us about technology’s unique power to help people connect with each other, and in doing so, defying the isolation and fear that accompany serious health conditions. Bill Evans from Watson Health showed us how Watson is changing the face of medical research with its ability to “read” thousands of medical journals and white papers in unimaginable speeds in an effort to increase the safety and efficacy of clinical trials drugs.

Our Healthcare Startup Sharktank brought innovative thinking to the forefront of consumer health. Movi Interactive is incentivizing fitness tracker users in unique ways by gamifying their experiences to drive usage. Through their platform, Medprowellness is connecting consumers with clinicians, nutritionists, and personal trainers to provide a personalized layer of accountability to their 360-degree approach to health and wellness.

The marketer in me was excited about all the new ways data will continue to fuel our insights. Finding new ways to visualize data is critical, according to David Davenport Firth, particularly since 75% of physicians admit to not understanding the statistics in journals. Back to the topic of wearables… For a while now, marketers have been talking about the endless data streams being collected from wearables. Patrick Henshaw and his startup, Strap, can aggregate data from wearables, smartphones, and other apps, allowing marketers to draw insights from real-time human data. On a similar note, there was Pranav Yadav, whose company Neuro-Insight can help marketers and brands optimize their creative by analyzing the neuro-responses of their consumers.

We are at the crossroads of health, wellness, technology, and marketing. Ryan Olohan from Google reinforced the fact that like all successful companies, healthcare brands need to innovate or die. Companies like Kodak and Blockbuster didn’t, while companies like Uber and Expedia have changed their respective industries forever. As marketers in the healthcare space, we all need to look beyond our comfort zones. We need to encourage our brands to look beyond, as well.

This article was originally posted on Ivan Ruiz Graphic & Web Design.

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, agency life, behavior change, Blogging, Branding, content marketing, Creativity, CRM, Culture, Customer Relationship Marketing, Data, Design, Digital, Digital Advertising, Global Marketing, Great Ideas, Healthcare Communications, Innovate, Multi Channel Marketing, Patient Communications, Payer Marketing, Physician Communications, Social Media, Statistics, Strategy, Technology | Leave a comment

4 Key Takeaways From the OCHWW Marketing Summit 2015

Martha CMO Blog2_ED

Behind the scenes look at OCHWW’s Innovation Lab

The OCHWW Marketing Summit took place on September 24, when attendees from all over the world came together to discuss marketing in the age of person-centric healthcare. Throughout the day, speakers from the pharmaceutical and technology industries echoed four main themes surrounding the state of healthcare today: innovation, personalized medicine, social healthcare, and the vast amounts of health data being generated every day.

Innovation must play a larger role in healthcare organizations going forward. According to Chris Halsall of OgilvyRED, it cannot just be a hobby of an organization, it must be the core. As Ryan Olohan from Google Health puts it, “Technology comes at us like a train—you’ve got to innovate or get run over.” Innovation in healthcare comes down to courage, and we must change the culture of healthcare organizations to embrace digital innovation.

Personalized medicine
Personalized medicine is the intersection between biology and technology. With today’s technology, we have the tools to get the full picture of the patient—molecular, clinical, and demographic, according to Niven Narain of Berg Health. With that, we can deliver personalized precision medicine, giving the right patient the right drug at the right time to lead to better health outcomes. Jeff Arnold of Sharecare states that this ultra-personalization of healthcare will empower consumers to take control of their own health.

Social healthcare
Health is the most personal thing there is, but as it stands today, healthcare is the least personal. One of the most significant benefits of technology is facilitating human connection in healthcare. Health is now social, and patients are talking about your pharma brand whether you are part of the conversation or not. Be part of the conversation.

Health data
Vast amounts of health data are being generated every day, and we need a system to parse it to make it useful, according to Bill Evans of IBM Watson Health. David Davenport-Firth of Ogilvy CommonHealth Worldwide states that patients can’t make health decisions if they don’t understand their health data. Cognitive systems like Watson can democratize health insights to better patients’ lives, and responsive and dynamic representations of health data can personalize and humanize patients, leading to better health outcomes.

Healthcare is undergoing a transformation unlike any it’s seen before. Looking to the future, healthcare organizations must be disruptive by embracing innovation and putting patients at the center of everything that they do.

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, agency life, Analytics, behavior change, Branding, Creativity, Culture, Data, Design, Digital, Digital Advertising, Global Marketing, Great Ideas, Healthcare Communications, Marketing, Social Media, Strategy, Technology, Wearable Health Technology | Leave a comment

Wait Up!

Karen Rose Redworks Blog Image_EDCycling down the Greenway in NYC, I became separated from my friends and lost sight of them. I stopped and called my boyfriend from my cell phone but wasn’t entirely certain he had brought his phone with him on his bike. I figured, nothing to do but keep cycling and hopefully catch up with them.

Then my chain broke. Geez! I made another call, then sat down and thought, “Now what?”

Three options came to mind: 1) Find a bicycle store and get the chain repaired; 2) Walk my bike to the Port Authority and take a train home; or 3) Stay on the Greenway and wait in the hopes that my cycling friends would come back and find me.

I dismissed Option 1 quickly: If I left the Greenway, I wouldn’t know if they came by while I was gone. I wasn’t keen on Option 3: Wait?! For how long? No guarantee they’re coming back the same way. My impulse reaction was Option 2: Take a train home and catch up with my friends later.

And I almost went with Option 2. But then I forced myself to slow down, resist a gut response for immediate action, and think it through. What if I walked all the way to the PA and found that I couldn’t take my bike on the train? Then I’d need to return to the Greenway and, well…same concerns as Option 1.

I reluctantly gave in and decided to wait. Not thirty minutes later, I saw my friends cycling toward me. My knights in shining Under Armour! They rigged my chain and got me back in the saddle in record time. And off we went. Problem solved! And all it took was the presence of mind to take a deep breath…and…wait.

On the ride back to the George Washington Bridge, I pondered how often at work we are presented with similar decision-making each and every day. We may not have all the information we need, yet we often need to “keep the job moving.”

But how often do we end up with redos? Or missing something? Or wasting precious time and resources moving something to the next step that would have been better to wait for clearer direction?

Sometimes pausing is the best action you can take.

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in agency life, Blogging, Culture, Great Ideas, Humor, leadership, Learning, Work-life | Tagged | Leave a comment

Mobile in Healthcare: The Future?

Mobile Healthcare Blog ImageIn the past few years, mobile technology has changed the way consumers interact with their service providers. Whether ordering a cab to one’s exact location within minutes or getting groceries delivered in a matter of hours, there seems to be an app for everything. The healthcare industry is no exception to this trend. Mobile health data helps patients, doctors, and pharmaceutical companies in new and innovative ways.

Mobile technology is changing the way doctors and patients interact with both the healthcare system and with one another. The fitness wearables trend has put the power of transforming one’s health and body into the hands of the consumer. People use wearables and other mobile devices to get constant data feedback on their heart rate, steps, calories burned, etc. Many of these apps then organize and share this information in an easy-to-understand way, allowing consumers to make better decisions about their health. Patients can also use new apps, such as ZocDoc, which provide up-to-date appointment availability, enabling users to schedule visits with doctors as quickly and conveniently as possible. In fact, even more specific apps exist, such as Castlight, which compares prices of MRIs and other tests to find the most affordable options in a given location.1

Healthcare professionals also use a number of different apps to improve patient care and treatment. Indeed, there are entire sections of Apple’s App Store devoted to apps for doctors.2 Perhaps one of the most useful features in many of these apps is the ability to look up information right at the patient’s bedside. Quickly searching for certain symptoms can save crucial time for both the doctor and patient and may facilitate a more accurate diagnosis. Moreover, certain apps will soon offer on-the-go monitoring functionality, providing live feeds of patients’ vitals right to their doctors’ mobile devices. This continuous supply of information can optimize patient care and improve the healthcare system on a wider scale.

These mobile technologies are not just changing the way healthcare works in developed countries. Mobile has been incredibly helpful in transforming and improving the healthcare systems of many third world countries. This technology helps serve underprivileged societies by “addressing challenges such as reducing material and infant mortality rates, combatting infectious disease, creating awareness of HIV and delivering nutritional health and treatment for a variety of health conditions remotely.”3 CliniPAK360 is one app that has transformed treatment in Africa. The app works by allowing healthcare workers to input symptoms and information about a patient, which is then used to analyze and diagnose serious conditions. Other hospitals in Africa are using phones or tablets with preloaded medical information, which can be critical for saving time and effort in diagnosing and treating patients.

Mobile is also changing the way that healthcare marketers target consumers. Instead of simply “pushing pills,” companies now make their brands interactive and interesting to consumers, helping to change their brand image. Mobile apps help patients track their own health and progress and supply pharma companies with more data to effectively target consumers. Merck created MerckEngage, which provides health tracking services and has over 100,000 users from whom Merck can collect new insights and information. Geisinger Health System also launched an app on a small scale that studied “metrics like patient acceptance and treatment adherence to decide which solutions to these issues could be deployed on a broader scale” based on data they received from the app. Additionally, mobile apps can also help with medicine adherence by understanding which patients do not follow their prescription instructions and targeting them with more precise reminders. Pharma companies can leverage this data revolution to obtain the most accurate and useful marketing information yet.4

I have seen this mobile technology in my short time here at Ogilvy CommonHealth. In the past few weeks, I have helped work on an app which tracks a user’s sleep habits through either manual input or syncing up with a wearable device like Jawbone or Fitbit. This app is mutually beneficial as it helps the owners collect data on sleep habits nationwide, and helps users achieve greater awareness of their sleeping behaviors.

The central theme among all of these healthcare apps is optimization, data collection, and a better understanding of disease perception. Large databases of patient and consumer information now exist, which can be analyzed to streamline and improve patient experience, outcome, and overall health.5 It remains unclear how far these apps can take us, or if a piece of technology will ever be as good as a doctor’s intuition, but the continuing innovations provide a glimpse into the future of healthcare.

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.
Read More »

Also posted in advertising, Analytics, behavior change, Data, Design, Digital, Healthcare Communications, Medical Education, Patient Communications, Physician Communications, Strategy, Wearable Health Technology | Leave a comment

Helping Clients Navigate Compliant Communications for FDA-regulated Products

Helping Clients Navigate Compliant Communications for FDA-regulated Products IMAGE_EDVANITY URLS: Google Paid Search Engine Marketing (SEM) Changes
• Redirecting ad changes effective January 12, 2016
• Prohibiting ads where vanity URLs are utilized and dramatically different from the destination URL

Google has announced significant changes in their paid search engine advertising policies with regard to pharmaceutical products. The change that we are addressing here deals with vanity URLs, and their respective redirecting ads, that will take place in January 2016. The bottom line is that Google will no longer allow vanity URLs in an effort to provide consumers with more “clarity and transparency.”

Google has a long-standing policy prohibiting any ads where the destination URL differs dramatically from the display URL. Please note, this prohibition is not exclusively for pharmaceutical products—it has been Google’s practice across the board. Up until now, the pharmaceutical industry had been the exception to the rule. The reason for the exception was because in many cases, information seekers will not know the name of a drug, but will understand and know the symptoms/disease state information.

FDA background information
Previously, the FDA never objected to marketers utilizing vanity URLs and/or redirecting ads. These URLs/ads typically do not directly promote the name of a prescription product. Instead they lend themselves more to a disease state or descriptive nature, and then redirect users to another location or URL where they will see branded information specific to the prescription drug and/or disease state. Vanity URLs/redirecting ads are not exclusive to online SEM use, and are also used in print ads, television commercials, billboards, postcards, and more.
In March 2009, the FDA sent out 14 violation letters regarding search engine marketing practices of 48 brands. Thirteen of those violations referred to SEM ads running on Google. The FDA noted four types of violations in 2009:

  1. Omission of risk information, failure to meet requirements of 21 CRF 202.1(e)(5)(ii)
  2. Inadequate communication of indication
  3. Overstatement of efficacy
  4. Failure to use the required established name

Google’s reaction—what exactly is Google implementing?
Beginning in January 2016, Google will not permit pharmaceutical advertisers to have vanity URLs (such as “TreatmentforConditionX.com”) that redirect users to a BrandName.com website.

Pharmaceutical marketers will have the following options for vanity URLs:
Option 1


Sample ad showing company name as URL

Option 2
They can add “.com” to the company name.


Sample ad showing company name plus .com as URL

Option 3a (for prescription drugs, biologics, and vaccines)
They can display the phrase “Prescription treatment website” as the display URL.


Sample ad showing prescription treatment display URL

Option 3b (for medical devices)
They can display the phrase “Prescription device website” as the display URL.


Sample ad showing device display URL

All of these ads will be able to drive to pages on the brand.com or brandhcp.com website.

At the present time, this change has been instituted by Google only, and doesn’t lend itself to print, television, or other advertising mediums.

What does this mean for our clients?
Review and reassessment of live and proposed Google SEM campaigns where clients utilize vanity URLs need to be completed as soon as possible. New campaigns need to take these new rules into consideration during the tactical planning phase. Funds can be shifted to Yahoo and Bing, however there is the possibility that they may also follow suit.

Google has indicated a willingness to work with pharmaceutical clients to minimize potential negative impact to paid search campaign performance. Testing of the new formats will determine which type of units work best with various campaigns.

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Analytics, Apps, Brand Awareness, Branding, Clients, Content Strategy, Design, Digital, Digital Advertising, Healthcare Communications, Patient Communications, Physician Communications, SEO, Statistics, Strategy, Technology, Uncategorized | Tagged | Leave a comment

The Client’s Always Right…Except When They Aren’t

Darlene Dobry Med Mktg Blog Image EDIn a service industry, many of us live and die by the mantra, “The client’s always right.” We have long understood and served our role as agency partners and know that we need to passionately support our clients’ efforts.

But is it acceptable to challenge the clients’ wisdom and tell them from time to time that the path they want to take will not result in the best outcomes? That they should take greater risks and push themselves and their brands to greater heights? That they should not accept mediocre results when they can achieve greatness? That they should stop doing what the others are doing and break away from the pack?

Absolutely—this is our job, this is what true client partners should want and expect. We cannot simply nod our heads in approval if we truly care about our clients and the brands we support. We need to tell the truth―backed up with data, customer insights and market knowledge—and state it with conviction. When it’s out, the client will ultimately determine which direction to proceed, but they will do it knowing the potential “watch outs” or barriers to its success, and we can then work together to be armed with the ultimate plan.

It has been my experience that clients do appreciate partners who show passion, conviction and a commitment to doing what they believe is right. Most are not looking for order-takers or yes-men (and if they are, you may want to consider working with a new client).

In my office, I have a sign that says, “I’d agree with you, but then we’d both be wrong.” It’s not there to remind me that I’m always right—it’s a daily reminder to stand up for the brand and what you believe…always, even if it’s not necessarily popular. Of course, it’s critical to be able to back it up and deliver with diplomacy, grace and experience. In the end, the client drives the ultimate decision, and as their partner, we align, support them and drive to deliver the very best.

My best client relationships have been based on trust, truth and transparency, and respecting that it works both ways. There is immense power, transformative ideas and inspired problem solving that come from collective diverse thinking and challenging the status quo. Remember, in the words of David Ogilvy, “We only get a spark when the stone and flint are moving in opposite directions.”

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, agency life, behavior change, Branding, career decisions, Clients, Creativity, Culture, Design, Healthcare Communications, Learning, Partnerships, Strategy | Leave a comment

Immunotherapy: Has the Answer to Cancer Been Inside Us All Along?

Immunology Blog Image EDThis year over 1.6 million Americans will be diagnosed with cancer and nearly 600,000 people will die from the disease. That’s over 1600 people each day. The need for innovative therapeutic approaches to treat cancer has never been higher. To help fight the tumor, oncologists are literally looking within at new immunotherapeutic approaches aimed at unleashing the body’s own natural defenses.

The idea of immunotherapy isn’t a new one. Since the first studies of antibodies began in 1891, researchers have continued to investigate the potential of the immune system. But the idea held little more than promise.

But all that has changed.

Numerous breakthrough advancements in immunotherapy, with unprecedented results, have propelled the entire class forward. At this year’s Annual Meeting of the American Society of Oncology (ASCO), immunotherapy took front and center. Thousands upon thousands of oncologists crammed the educational sessions for just a glimpse of some of the new data being presented, CNN ran headline news stories from the congress, and even patients are aware and asking their physicians about the new therapies being researched.

Across the board, the pharmaceutical industry has started to mobilize behind the potential of immunotherapy unlike anything else seen before. Most of the major pharmaceutical companies already have one or more new drug candidates in development—and if they don’t, they are aggressively exploring opportunities to catch up.

Over 800 Clinical Trials With Immunotherapy Products
At present there are 844 ongoing or completed clinical trials with immunotherapy drugs across a wide range of tumor types. These trials include some of the most challenging cancers associated with the worst prognoses, like lung, stomach, brain, and melanoma. And new trials with new products and new regimens are added almost daily.

$35 Billion in Projected Sales
Analysts believe that annual sales for immunotherapy products in oncology will reach $35 billion a year.

60% of Cancers Will be Treated With Immunotherapy

Researchers believe that immunotherapy may become the dominant form of treatment in oncology, with nearly two out of every three cancer patients receiving some form of immuno-based therapy within the next decade.

While these numbers are staggering, the greatest benefit may be for the patients diagnosed with cancer. The early results from the emerging next-generation immunotherapy agents have rightfully captured the hopes of both patients and oncologists. With continued research and a little luck, these treatments may provide more than a treatment for a cancer, they may offer a cure.

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in clinical trials, Healthcare Communications, Medical Education, Medicine, Pharmaceutical, Physician Communications, Strategy | Tagged , | 1 Response

Does Size Always Matter?

How Pharma Engages With Its Followers Online

Social Network Blog Image_EDPharma is investing more heavily in social media than ever before; tweets are up 530% since 2013 and Twitter followers have increased by nearly 300%. So far, so good. Because more followers means more opportunities to get involved, and the more impact you make online, right?

But engaging in genuine, meaningful conversations about a corporate brand isn’t easy, and it’s important to ensure we don’t fall into the trap of focusing too much on numbers and not enough on engagement. Companies need to ensure they don’t build followers just to push out messages to anyone willing to pay attention. While people are increasingly more open to finding new knowledge on social media, they don’t want to wade through hundreds of pages of information, images or tweets to do so.

The balance between community size versus engagement is becoming more and more of a priority, and formed one of the focus areas for a recent report published by Ogilvy Healthworld, part of Ogilvy CommonHealth Worldwide (the health behavior specialists of Ogilvy & Mather).The report, Connecting the Dots: Which Pharma Companies Are Succeeding in the Social Media Space?, was the first of its kind to provide insights into which pharma companies are leading the way in integrated social media marketing strategies.

“We know that some pharma companies have been cautious in their approach to social media, but our report clearly demonstrates a dramatic and successful increase in activity,” said Rebecca Canvin, Social Media Manager at Ogilvy Healthworld, adding: “Social media has changed the way pharma companies communicate—it allows them to build corporate reputation and engage in genuine, meaningful conversations with audiences. For companies who want to stand out from the crowd, it’s time to be brave, get personal, educate and integrate social media into their wider marketing strategy.”

Interestingly, companies that ranked most highly in the audit weren’t necessarily those with the largest communities, but those who engaged their audiences through frequent activity. And it’s not hard to understand why the more active companies enjoy the most engagement with their followers—after all, social media in its very nature demands participation and interaction. But the companies that do it well manage to create content that is less about the organization and more about connection points or interests that followers share.

The report highlights that although the focus for pharma companies is still on building brand profile, the priority is turning to attracting, keeping and engaging with loyal followers. And to do this, the onus needs to shift to “quality over quantity.” It’s more powerful to engage with a small group of passionate followers, whether they’re consumers, doctors or media, than to blast one message to 10,000 followers and “see what sticks.”

And loyal followers will reward companies who engage continuously in this way—so really, shouldn’t we all be asking, how much does size matter?

Connecting the dots - infographic UK Post

To find out more on Connecting the Dots: Which Pharma Companies Are Succeeding in the Social Media Space? please visit: http://bit.ly/1P5R5Ws

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Apps, behavior change, Brand Awareness, Branding, Content Strategy, Culture, Data, Design, Digital, Digital Advertising, Healthcare Communications, Public Relations, Social Media, Strategy, Technology | Leave a comment

The Next Phase of Pharmaceutical Value Propositions Needs to Include the Real Meaning of Synergy

Synergy Blog ImageExpress Scripts recently issued a report on drug spending that made some headlines in the business press.[1,2] This compelling report shows that, from the perspective of a pharmacy benefit manager (and its pharmacy claims database), evidence confirms the trends of increased drug spending, particularly in the subset of patients that consumes at least $100,000 worth of drugs annually:

• The population of patients that takes at least $100,000 worth of drugs has almost tripled from 2013 to 2014
• Compounded drugs were the 3rd highest driver of the trend, behind HCV antivirals and oncolytics
• 9 out of 10 patients with drug costs over $50,0000 used specialty medications
• Men and baby boomers (those aged 51-70) make up the majority of those with high drug costs
• Comorbidities and polypharmacy were prevalent among patients with high drug costs

Glenn Stettin, MD, the SVP of Clinical, Research, and New Solutions, outlines in this report implications and recommendations, most of which are feasible for a PBM to consider:

• Eliminate wasteful spending and improve medication adherence
• Manage specialty and traditional medications together
• Pioneer new approaches in cancer care that both offers patient access and sustains payer affordability

While these are important recommendations, there is an opportunity for pharmaceutical manufacturers to consider extending and enhancing the value propositions of their drugs, and it relates to the “comorbidities and polypharmacy” finding in this report, which is pretty remarkable. The report shows that:

• Among patients whose drug costs reached $100,000, more than one-third were treated for more than 10 conditions
• More than 60% were taking more than 10 medications
• One in four patients had prescriptions from at least 4 different prescribers
• More than half of patients with $100,000 in drug costs were prescribed medications by physicians from at least 4 difference specialty areas

Now, as we read daily in the business press, the drug industry is facing pushback about its pricing of newer agents (specifically HCV antivirals and oncolytics). This resistance from customers is normal, and has taken various forms of stricter precertifications and/or formulary requirements.[3] Recently, legal patent challenges have surfaced; in some countries, various advocates are asking that patents on drugs be voided, so that generic competitors can appear earlier.[4] Nonetheless, evolving industry forces, such as comparative effectiveness research, constrained health care budgets of some payers, and new competitors have started to create a new equilibrium between sellers and buyers, and these forces are helping to more quickly vet winners and losers. It is encouraging to see the manufacturers (particularly of HCV and cancer drugs) refine the value propositions of their drugs, which now include cures for some patients.[3]

But disease is multifactorial (and, as the ESI report shows, multiple diseases are, too), and treatments often need multiple approaches. Manufacturers may need to extend the current value proposition of “one drug that treats one disease at one time” and add it to the complicated heath care mix that includes other variables, for example:

• Combination therapies (with other drugs, including competitors and/or generics, and with other modalities such as devices, diet, surgery, etc.)
• Timing or sequence of treatments (ie, phase of the disease)
• All of the factors in “care coordination” (ie, different physicians, different specialties, different settings)

In other words, manufacturers need to demonstrate the synergy produced by their drugs. “Synergy” is often misused, but I like the Merriam-Webster definition of synergy as “a mutually advantageous conjunction or compatibility of distinct business participants or elements (as resources or efforts).”[5] Certainly some treatment guidelines, pathways, and medical policies attempt to address these multiple variables in health care. But manufacturers can bring their significant credibility in clinical research and patient experience to identify, define, and demonstrate the specific opportunities that optimize their drugs’ performance. They are best-suited to do so, and the customers are receptive to that type of message. (Note: as this heads to posting, 2 manufacturers are reported to have taken this approach and are studying their oncology drugs in combination.[6])

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.


1. Super Spending: US trends in high-cost medication use. May 2015. http://lab.express-scripts.com/insights/drug-options/super-spending-US-trends-in-high-cost-medication-use. Accessed May 19, 2015.

2. Growth of patients with $50K annual drug tabs skyrockets. Fierce HealthFinance. May 17, 2015. http://www.fiercehealthfinance.com/story/growth-patients-50k-annual-drug-tabs-skyrockets/2015-05-17). Accessed May 19, 2015.

3. Gilead’s $1,000 Pill Is Hard for States to Swallow. The Wall Street Journal. April 8, 2015. http://www.wsj.com/articles/gileads-1-000-hep-c-pill-is-hard-for-states-to-swallow-1428525426. Accessed May 21, 2015.

4. High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents. http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html. Accessed May 20, 2015.

5. Merriam-Webster Online. http://www.merriam-webster.com/dictionary/synergy. Accessed May 21, 2015.

6. AstraZeneca and Lilly to test new cancer drug combination. Reuters. May 29, 2015. http://www.reuters.com/article/2015/05/29/us-astrazeneca-eli-lilly-cancer-idUSKBN0OE0HU20150529. Accessed May 29, 2015.

Also posted in clinical trials, Data, Education, Healthcare Communications, Medical Education, Medicine, Pharmaceutical, Science, Strategy, Technology | Tagged | Leave a comment

Satisfying Patient Needs Across Generations via Patient Portals

When it comes to healthcare, patients from the “Greatest Generation” to Millennials want three things: 1) a strong patient-physician relationship, 2) easy-to-understand healthcare information, and 3) this information? preferably in a digital format. How do we accomplish all three? Before we answer that question, let’s take a look at how different generations access healthcare information.

Monica Wong Blog Image

The “Greatest Generation” (Age 65+)
While almost 60% of people ages 65 and older use the Internet on a daily basis, this generation of patients are heavily influenced by their doctors when it comes to recommendations, health information and referrals. However, children and caretakers of this generation, Baby Boomers, may also play a role in making these decisions on behalf of the “Great Generation.”

Baby Boomers (Age 45-65)
While this generation is also influenced by physicians, Boomers are more likely than the “Greatest Generation” to research their options, challenge assumptions and rely on peer-to-peer conversations to make their healthcare decisions. 79% of Baby Boomers go online every day or almost every day. A Google/Nielsen Boomer Survey also reported that 78% of Baby Boomers have searched for health information after seeing something on TV. Baby Boomers also influence healthcare decisions of their Gen X and Millennial children.

Gen X (Age 30-45)
According to research done by Smith & Jones Healthcare Marketing, Gen X are only moderately responsive to healthcare advertising. Since this generation is the first to experience the digital age, Gen X shops for healthcare like they do for retail goods and services. They are partial to TV and in-office messages compared to other forms of marketing channels, but they also have a tendency to search for ratings and reviews online, as experience matters to them.

Millennials (Age 20-30)
Like Gen X, Millennials highly value positive patient experiences. They are young and healthy and as a result, they mainly use healthcare for primary care, urgent care and OB/GYN. Online advertising, TV and in-office messages are the best ways to reach them close to the care decision. Millennials seek information from a variety of sources, including online, social networks and word of mouth.

Satisfying Patient Needs Across Generations With Patient Portals
What do these generations of patients all have in common? They want positive patient experiences with their physicians. They want information they can easily understand and they want easy access to it online. So how do we satisfy these needs? Patient portals. Why? Because increasing positive patient outcomes and experiences begins with making physicians more accessible when patients have concerns. Physicians can distribute timely and relevant information to their patients on a digital platform that can be accessed 24/7. According to the American Academy of Family Physicians, 41% use portals for secure messaging, 35% use them for patient education, and 30% use them for prescribing medications and scheduling appointments.

How Can Marketers Leverage Patient Portals?
By repurposing existing healthcare marketing material and creating a depository for digital assets, these resources can be made available to HCPs who can then share these assets with their patients. Their patients will likely be more receptive to information as it is coming from a trusted source, their physicians, and through a channel they have easy access to. However, there are limitations.

Opportunities to Take Patient Portals to the Next Level
For elderly patients, additional features like the ability to increase portal font size is a simple fix. For digital natives, mobile-optimized portals can facilitate prescription refills and requests as well as schedule appointments. For non-native English speakers, portals available in different languages can dramatically improve patient services. But for those who do not have access to the Internet, we’ll have to find a way to close that gap. If you have any thoughts, please share in the comments below.

Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in Analytics, Data, Design, Digital, Digital Advertising, Healthcare Communications, Technology, Wearable Health Technology | Leave a comment